GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-09 and is reviewed periodically as new material appears.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
A study to test whether a new treatment has an effect (NCI) Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. (NLM) Phase 2 includes the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. (21CFR312) Phase II/III trial
In October 2023, Galloway promoted the false claim that Volodymyr Zelenskyy's wife Olena Zelenska had spent $1 million on jewelry in New York City, during the time of which Zelenska was actually in Canada. Galloway said that his source for the story was The Nation, but the publication that had actually reported this claim was a Nigerian newspaper of the same name. Regarding the Crocus City Hall attack in Russia, Galloway said he had "four pieces of evidence that lead [him] to believe that the United States, its NATO allies, and their puppet stump state Ukraine are, in fact, responsible for this massacre". In October 2024, at the 16th BRICS summit, Galloway criticised the British press at the event for "hating Russia" and suggested there was more media freedom in Russia than in Britain. In June 2025, Galloway participated as a speaker at the Forum of the Future 2050 in Moscow, a conference organised by tycoon Konstantin Malofeev. The guest list also included Elon Musk's father, Errol Musk, Russia's foreign minister Sergey Lavrov, economist Jeffrey Sachs and conspiracy theorist Alex Jones, among others. After going into self-imposed exile in Russia, Galloway said on his talk show that he supports Russia's war against Ukraine, calling it anti-imperialist and anti-colonialist. He praised Russia's military after it struck Yahodyn, on the Polish border, with a drone.
== Production and distribution == Entire illicit supply chains dedicated to collecting, processing, and reselling gutter oil have been discovered by regulators in China. Multiple low-end restaurants in China have been found to cook with gutter oil. Additionally, in 2012, the Chinese government accused a Chinese pharmaceutical company of using gutter oil as a precursor for the manufacturing of cephalosporin antibiotics. About two to three million tons of cooking oil containing cancerous substances are produced in China each year. In 2010 it was estimated that approximately one tenth of the meals consumed by people in China could contain gutter oil. Collected waste oil is sold to local workshops or small factories for cleaning and packaging. When sold to workshops it is often transported by bicycle mounted collectors; afterwards, the oil is held in 200-liter barrels at the workshops until it is processed. On other occasions the oil goes to industrial cooking oil refineries for further processing before it finally reaches its end purpose. Reprocessing of used cooking oil is often very rudimentary; techniques include filtration, boiling, refining, and the removal of some adulterants. It is then packaged and resold as a cheaper alternative to normal cooking oil. Another version of gutter oil uses discarded animal parts, animal fat and skins, internal organs, and expired or otherwise low-quality meat, which is then cooked in large vats to extract the oil. Some lower-market restaurants have long-term purchase agreements with oil recyclers for selling their used oil.
allosome Also sex chromosome, heterochromosome, or idiochromosome. Any chromosome that differs from an ordinary autosome in size, form, or behavior and which is responsible for determining the sex of an organism. In humans, the X chromosome and the Y chromosome are sex chromosomes.
Sources: en.wikipedia.org
=== MP for Henley: 1974–2001 === Heseltine, by now a junior minister in the Heath government, was now forced to apply for a new candidacy, often in competition with other sitting Conservative MPs whose seats were also due for abolition. He applied for Mid Sussex in competition with Ian Gilmour, but they lost to Tim Renton. He also applied for Mid-Oxfordshire but lost to Douglas Hurd. In 1972 Edward Heath attempted to persuade Heseltine, a strong supporter of his, to challenge Powellite MP Ronald Bell for the Conservative nomination for the new seat of Beaconsfield. Heseltine wrote that he was "tempted" to enter the lists at Beaconsfield, but did not actually do so. Crick writes that he reached the final shortlist of four against Bell, before being "apparently persuaded" to withdraw. Bell's campaign within the local Conservative ranks was masterminded by Hugh Simmonds, chairman of the Young Conservatives, and he narrowly won. Heseltine was one of 180 applicants for the safe Conservative seat of Henley (the constituency association of which was known as North Oxfordshire), whose MP John Hay was stepping down. He reached the final shortlist of three along with two other sitting MPs, William Shelton and Norman Fowler, and in September 1972 was selected as candidate with a clear majority at the first ballot. Part of the reason was that the Association wanted a wealthy MP who would not be distracted by the need to earn money in business as Hay had been. He maintained a constituency home in Crocker End, near Nettlebed, and still maintained a London home at Wilton Crescent.
== Professional career == Soon after obtaining his Ph.D. degree, Tej worked for a year as a lecturer at the University of Indore. He then spent more than two years (1978–1980) as an Alexander von Humboldt / Max-Planck, post doctoral fellow in the German laboratory of Professor Robert Huber, who later received the Nobel Prize. After his return to India he worked as a reader at Sardar Patel University (1980–83) and an additional professor (1984–85) in the Department of Biophysics at the All India Institute of Medical Sciences, New Delhi. He was appointed professor and head of the department in 1986 [2] [3]
Cultivation methods resulting in larger yields are categorized as "bulk growing". Bulk growing allows cultivators to operate on a larger scale, but require a greater investment of time, money, and knowledge. While small-scale grows utilize spore syringes to inject spore solution into cakes, bulk methods instead use grain spawn as primary nutrition for the subsequent growth. Additionally, cultivators must develop solid sterile technique in working with agar. Instead of inoculating grain with spores, growers instead germinate spores on agar plates, then transfer the resultant healthy mycelium to the grain jars. Once the grain is colonized with clean mycelial growth, users inoculate their bulk substrates with the grain in a process known as "spawning." Bulk substrates are frequently a mix of coir, vermiculite and gypsum due to not requiring pasteurization or sterilization. However, some utilize blends of manure-based substrates or straw; substrates which always require pasteurization with open-air spawning. After spawning, the healthy mycelium will colonize the bulk substrate, and given proper conditions, eventually fruit mushrooms. Terence and Dennis McKenna made P. cubensis particularly famous when they published Psilocybin: Magic Mushroom Grower's Guide in the 1970s upon their return from the Amazon rainforest, having deduced new methods (based on pre-existing techniques originally described by J.P. San Antonio) for growing psilocybin mushrooms and assuring their audience that P. cubensis were amongst the easiest psilocybin-containing mushrooms to cultivate.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.